JPS6440426A - Antitumor agent - Google Patents

Antitumor agent

Info

Publication number
JPS6440426A
JPS6440426A JP62197395A JP19739587A JPS6440426A JP S6440426 A JPS6440426 A JP S6440426A JP 62197395 A JP62197395 A JP 62197395A JP 19739587 A JP19739587 A JP 19739587A JP S6440426 A JPS6440426 A JP S6440426A
Authority
JP
Japan
Prior art keywords
salt
antitumor agent
lower alkyl
membered
ointment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP62197395A
Other languages
Japanese (ja)
Inventor
Hiroshi Furukawa
Yukihiro Nishiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Priority to JP62197395A priority Critical patent/JPS6440426A/en
Publication of JPS6440426A publication Critical patent/JPS6440426A/en
Pending legal-status Critical Current

Links

Landscapes

  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

PURPOSE:To obtain an antitumor agent containing acridone alkaloid or a salt thereof as an active ingredient. CONSTITUTION:A compound shown by the formula (R<1> is H or lower alkanoyl; R<2>-R<8> are H, lower alkyl, hydroxy, lower alkoxy, lower alkanoyloxy or R<2> and R<3> or R<3> and R<4> may be bonded to form 5-membered or 6-membered oxygen-containing heterocyclic ring; R<9> is H or lower alkyl) or a salt (e.g. hydrochloric acid or maleic acid) as a main component is blended with a conventional drug additive and pharmaceutically manufactured by a conventional procedure to give the aimed substance. The material can be prepared into a dosage form such as tablet, capsule, granule, solution, ointment, gel, suspension or cream. A dose is 0.1-2,000mg daily and administered once - dividedly several time.
JP62197395A 1987-08-07 1987-08-07 Antitumor agent Pending JPS6440426A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP62197395A JPS6440426A (en) 1987-08-07 1987-08-07 Antitumor agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP62197395A JPS6440426A (en) 1987-08-07 1987-08-07 Antitumor agent

Publications (1)

Publication Number Publication Date
JPS6440426A true JPS6440426A (en) 1989-02-10

Family

ID=16373792

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62197395A Pending JPS6440426A (en) 1987-08-07 1987-08-07 Antitumor agent

Country Status (1)

Country Link
JP (1) JPS6440426A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014008A1 (en) * 1989-05-25 1990-11-29 Sloan-Kettering Institute For Cancer Research Methods and compositions for inhibiting tumor cell growth
WO1997012871A1 (en) * 1995-03-31 1997-04-10 Eisai Co., Ltd. Acridone derivative

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014008A1 (en) * 1989-05-25 1990-11-29 Sloan-Kettering Institute For Cancer Research Methods and compositions for inhibiting tumor cell growth
WO1997012871A1 (en) * 1995-03-31 1997-04-10 Eisai Co., Ltd. Acridone derivative

Similar Documents

Publication Publication Date Title
FI872864A (en) Process for the preparation of pharmaceutically active benzimidazole compounds
EP0382077A3 (en) Diaryl-substituted heterocyclic compound, its preparation and medicaments and cosmetics made thereof
ES8801659A1 (en) Pyrano[3,2-c]pyridine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them.
IL80403A (en) Heterocyclic analogs of mevalonolactone and derivatives thereof,their preparation and pharmaceutical compositions containing them
PT86186A (en) Process for the preparation of benzimidazol derivatives and of pharmaceutical compositions containing the same
IL92799A0 (en) Benzimidazole derivatives with gastric acid inhibition and process for its preparation
GB1515241A (en) Beta-lactam antibiotics
JPS57109721A (en) Carcinostatic agent
JPS6440426A (en) Antitumor agent
ES8307224A1 (en) Pyrazoline derivatives, processes for their preparation and pharmaceutical formulations containing them.
JPS6452721A (en) Diabetic remedy containing 7-thiapprostaglandin e1 as active ingredient
GB1460325A (en) Pharmaceutical composition intended for relieving pain and producing analgesia
JPS6429312A (en) Antiallergic agent
JPS643121A (en) Remedy for endometriosis
ES2005777A6 (en) Hydrogenated pyridine derivatives.
GB1260857A (en) IMIDAZO-3H-(4,5-b)-PYRIDINE DERIVATIVES
JPS6425728A (en) Nootropic (noesis improving agent)
IL42201A (en) 2-((1-benzylcyclopentyl)-imino)pyrrolidine
JPS55111470A (en) Geldanamycin derivative, its preparation, antitumor drug comprising it as active ingredient
GB1413407A (en) Dihydropyrido-pyrimidine derivatives their preparation and therapeutical use
JPS6429313A (en) Enzyme inhibitor
GB1477996A (en) Quinolizine derivatives and their preparation
GB1505859A (en) Azetidinone derivatives
JPS6463520A (en) Prolactin secretion inhibitor
IE791205L (en) Novel oxothia compounds, processes for their preparation,¹pharmaceutical preparations containing these compounds and¹such compounds for therapeutic use